Text Size
26 studies found for:    Open Studies | "Pheochromocytoma"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
Conditions: Extra-adrenal Paraganglioma;   Metastatic Pheochromocytoma;   Paraganglioma;   Recurrent Pheochromocytoma
Interventions: Drug: pazopanib hydrochloride;   Other: diagnostic laboratory biomarker analysis
2 Recruiting Dovitinib in Neuroendocrine Tumors
Conditions: Advanced Metastatic Paraganglioma;   Advanced Metastatic Pheochromocytoma;   Recurrent Paraganglioma;   Recurrent Pheochromocytoma;   Unresectable Paraganglioma;   Unresectable Pheochromocytoma
Intervention: Drug: Dovitinib
3 Recruiting Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma;   Essential Hypertension
Interventions: Other: plasma EM66 & CgA levels assessment;   Other: usual follow up with regular EM66 & Cga levels assessment
4 Recruiting Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Drug: Sunitinib
5 Recruiting Diagnosis of Pheochromocytoma
Condition: Pheochromocytoma
Intervention:
6 Available Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
7 Unknown † RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Conditions: Pheochromocytoma;   Extra-Adrenal Paraganglioma;   Non-functioning Carcinoid
Intervention: Drug: RAD001
8 Not yet recruiting MIBG for Refractory Neuroblastoma and Pheochromocytoma
Conditions: Relapsed/Refractory Neuroblastoma;   Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131I-MIBG);   Drug: Potassium iodide solution;   Drug: G-CSF
9 Recruiting Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Conditions: Neuroblastoma;   Pheochromocytoma
Intervention: Radiation: iobenguane I 131
10 Available 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma (Relapsed or Refractory);   Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG);   Drug: 131 I-MIBG
11 Available Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
12 Recruiting First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
Condition: Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
Interventions: Drug: Sunitinib;   Drug: Placebo
13 Recruiting Phenoxybenzamine Versus Doxazosin in PCC Patients
Condition: Pheochromocytoma
Interventions: Drug: Phenoxybenzamine;   Drug: Doxazosin
14 Available Expanded Access Protocol Using I131-MIBG
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
15 Unknown † Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide
16 Recruiting Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma
Condition: Pheochromocytoma
Intervention:
17 Unknown † Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Procedure: diagnosis methods
18 Unknown † 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
Conditions: Pheochromocytoma;   Neuroblastoma;   Paraganglioma;   Medullary Thyroid Carcinoma;   Carcinoid Tumors
Intervention: Drug: 123I-meta-iodobenzylguanidine
19 Recruiting Adrenal Tumors - Pathogenesis and Therapy
Conditions: Adrenal Tumors;   Adrenocortical Carcinoma;   Cushing Syndrome;   Conn Syndrome;   Pheochromocytoma
Intervention:
20 Unknown † Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot
Condition: Chromaffin-tissue Derived Tumors
Intervention: Other: Scintigraphy in 123I-IBZM
To Top

Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results
† Indicates status has not been verified in more than two years